{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:39:22Z","timestamp":1778693962460,"version":"3.51.4"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T00:00:00Z","timestamp":1666569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Facial persistent erythema is recognized as difficult feature to treat in rosacea. Topical Oxymetazoline cream 1% has been used to treat persistent facial erythema in rosacea patients for some years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To quantitatively synthesize the benefits and harms of Oxymetazoline cream 1% in real\u2010world clinical management of treatment response and adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The clinical researches before June 1, 2022 published on online databases including PubMed, Web of Science, Embase and Cochrane Library were meta\u2010analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 2298 participants were included, and the improvement rate of two\u2010grade Clinician Erythema Assessment score (CEA) and Subject Self\u2010Assessment for rosacea facial redness score (SSA) in Oxymetazoline group was 38% (95%CI 28\u201348) and 25% (95%CI 22\u201327), respectively, at the 4th week of the dosing. The comprehensive rate of treatment\u2010related TEAEs in Oxymetazoline group was 7% (95%CI 5\u20138). The rate of stinging\/burning was 15% (95%CI 10\u201319), pruritus was 15% (95%CI 9\u201322), dryness was 23% (95%CI 18\u201328), and scaling was 17% (95%CI 12\u201322) in analysis of dermal tolerability. And topical Oxymetazoline cream 1.0% presented a very low rebound rate of erythema (1%, 95%CI 0\u20132).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These real\u2010world data on Oxymetazoline cream 1% in rosacea\u2010associated erythema may help making clinic decision and informing treatment expectations, and more clinic trials on longer\u2010term dosing or the combination treatment with oral medication and energy\u2010based therapy are worth exploring.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jocd.15467","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T06:08:44Z","timestamp":1665727724000},"page":"103-110","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Benefits and safety of Oxymetazoline cream 1% on rosacea\u2010associated erythema: A systematic review and analysis of clinical evidence"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8907-3123","authenticated-orcid":false,"given":"Xin","family":"Yuan","sequence":"first","affiliation":[{"name":"Department of Dermatology Guizhou Provincial People's Hospital  Guiyang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Yin","sequence":"additional","affiliation":[{"name":"College of Medical Humanitles Guizhou Medical University  Guiyang China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,10,24]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1506630"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.049"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192487"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.08.028"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2017.1370370"},{"issue":"3","key":"e_1_2_13_7_1","first-page":"290","article-title":"Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: findings from the second Reveal trial","volume":"17","author":"Baumann L","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.027"},{"issue":"3","key":"e_1_2_13_9_1","first-page":"308","article-title":"Phase 2 randomized, dose\u2010ranging study of oxymetazoline cream for treatment of persistent facial erythema associated with rosacea","volume":"17","author":"DuBois J","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.037"},{"issue":"1","key":"e_1_2_13_11_1","first-page":"97","article-title":"Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: findings from the first REVEAL trial","volume":"17","author":"Kircik LH","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"e_1_2_13_12_1","first-page":"1201","article-title":"Topical oxymetazoline cream 1.0% for persistent facial erythema associated with rosacea: pooled analysis of the Two phase 3, 29\u2010day, randomized, controlled REVEAL trials","volume":"17","author":"Stein\u2010Gold L","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"e_1_2_13_13_1","first-page":"621","article-title":"Clinically relevant reduction in persistent facial erythema of rosacea on the first day of treatment with oxymetazoline cream 1.0","volume":"17","author":"Tanghetti EA","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.Ed000142"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017740139"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2017.11.001"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.2741\/s105"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.09012fp"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.23439"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.23176"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.23253"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/ppa.S115708"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.15467","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jocd.15467","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.15467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T13:45:51Z","timestamp":1692539151000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.15467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,24]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1111\/jocd.15467"],"URL":"https:\/\/doi.org\/10.1111\/jocd.15467","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,24]]},"assertion":[{"value":"2022-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}